Navigation Links
Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Date:6/28/2010

ORLANDO, Fla., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.  The analysis showed that higher C-peptide levels had a statistically significant correlation with a decrease in two distinct measurements of glucose variability, confirming that C-peptide is a robust clinical marker for beta cell function which becomes impaired in type 1 diabetes.  Measurement of C-peptide has been endorsed by FDA as the primary endpoint for clinical trials of therapies that are designed to preserve beta cell function in new-onset type 1 diabetes and is the primary endpoint to evaluate the efficacy of otelixizumab in the DEFEND-1 clinical trial, with results from DEFEND-1 expected in the first half of 2011.  

The pre-dose baseline data from DEFEND-1 represents one of the first comprehensive studies to correlate higher C-peptide levels with lower blood glucose variability in patients with type 1 diabetes.  These results are clinically meaningful because blood glucose variability may be a risk factor for short- and long-term complications, including severe hypoglycemia and microvascular disease, in patients with type 1 diabetes.  The analysis from the DEFEND-1 study was presented at a poster session of the 70th Scientific Sessions of the American Diabetes Association (ADA) taking place June 25 through June 29 in Orlando, Florida. 

"We are gratified that the analysis of baseline data from our DEFEND-1 clinical trial may contribute to a better understanding of new-onset type 1 diabetes and
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
2. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
3. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
4. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
5. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
6. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
9. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
10. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
11. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Asia-Pacific ... http://www.reportlinker.com/p02353210/Asia-Pacific-Infusion-Therapy-Device-Market.html Abstract: The ... therapy devices included volumetric infusion pumps, syringe infusion ... connectors and stopcocks. These categories are segmented based ...
(Date:9/2/2014)... 2, 2014 The Pharmaceutical Care Management Association ... (PBMs), today filed a lawsuit in Iowa ... Iowa law that restricts tools used ... state,s employers and consumers.  The law—HF ... restricting the use of Maximum Allowable Cost (MAC) lists ...
Breaking Medicine Technology:Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12
... ZURICH, December 9, 2011 NHS National ... ALFApump System Sequana Medical announced today the ... System commissioned by the National Innovation Centre, the NHS ... up the development and use of innovations that will ...
... ATLANTA, Dec. 8, 2011 CardioMEMS announced today that ... Devices advisory panel voted against the Champion Heart Failure ... allows cardiologists to monitor heart failure patients from their ... is safe with a vote of 9-1, the majority ...
Cached Medicine Technology:NHS National Innovation Centre Estimates Sequana Medical's ALFApump® System Could Save the NHS £50 Million in ascites Care Annually 2FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure 2FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure 3
(Date:9/2/2014)... Recently, BambooIndustry.com, an excellent company in ... strand woven bamboo floors to celebrate the ... its appreciation to the frequent callers, BambooIndustry.com launched a ... addition to strand woven floors, BambooIndustry.com provides many kinds ... floors, click strand woven floors, click lock floors, wide ...
(Date:9/2/2014)... EDT): In a Viewpoint published today in the ... of Boston researchers call for the implementation of taxes ... States. The researchers from the Friedman School of Nutrition ... Boston Children,s Hospital write that policies taxing nearly all ... people make meaningful dietary changes and substantially reduce health ...
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... 2014 The use of Xarelto (known ... growing at a rapid pace, even as Xarelto ... around the U.S., Bernstein Liebhard LLP reports. According to ... within a year of its 2011 launch, patients were ... a blood thinner that has been in use for ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
Breaking Medicine News(10 mins):Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2
... VA (March 29, 2011) Medicare coverage and ... to as virtual colonoscopy, has tripled in recent years, ... the Journal of the American College of Radiology ... to produce a three-dimensional visualization that permits a thorough ...
... -- New Orleans residents still faced a threefold higher ... was devastated by Hurricane Katrina in 2005, a study ... home and a poorly functioning health system likely contribute ... two-year post-Hurricane Katrina analysis of nearly 30,000 people. ...
... the risk of breast cancer, but the risk differs by ... analysis of the Women,s Health Initiative observational study. ... observed in non-obese women, but not in obese women. The ... body mass index (BMI) or waist circumference. Juhua ...
... that metabolic syndrome, a constellation of conditions that increases ... increase the risk of the two most common types ... AACR 102nd Annual Meeting 2011, held here April 2-6. ... the National Cancer Institute, said approximately one-third of the ...
... By Amanda Gardner HealthDay Reporter , SATURDAY, ... the ancient art of yoga appeared to halve the number ... atrial fibrillation. Three sessions of yoga a week ... and depression which often plagues patients with this condition, according ...
... 3 (HealthDay News) -- The use of a powerful ... the United States over the past five years, a ... drugs -- widely regarded as the last option for ... cause for concern because carbapenem-resistant bacteria are becoming more ...
Cached Medicine News:Health News:Nationwide utilization of virtual colonoscopy triples, study suggests 2Health News:Heart Attack Risk Plagues Post-Katrina New Orleans 2Health News:Smoking did not influence breast cancer risk among obese women 2Health News:Metabolic syndrome may increase risk for liver cancer 2Health News:Yoga May Also Calm a Dangerous Irregular Heartbeat 2Health News:Yoga May Also Calm a Dangerous Irregular Heartbeat 3Health News:Research Warns of Overuse of Powerful Class of Antibiotics 2
... the PROTG® GPS™ Self-Expanding Nitinol ... delivered on a commitment to ... PROTG GPS Stents take that ... by adding tantalum markers at ...
Colloidal Gold Conjugated, Streptavidin - 12 OD...
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 8-11; contains 1 bottle each of 20 nm and 40 nm Naked Gold...
Medicine Products: